aflibercept (Eylea)

following a full submission:

aflibercept (Eylea®) is accepted for use within NHS Scotland.

Indication under review: for adults for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion.

Aflibercept was associated with significant improvements over laser in visual acuity during a 6-month, randomized, double-masked phase III study in patients with branch retinal vein occlusion.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Aflibercept has previously been accepted by SMC for macular oedema secondary to central retinal vein occlusion. This advice now extends its use to patients with macular oedema secondary to branch retinal vein occlusion.